Granted Patent B2

US 12,258,393 · App. 17/325,743 · Granted Mar 25, 2025

Inventors: Matthew Germinaro (Philadelphia, PA); Christopher O'Brien (Lafayette Hill, PA); Jacqueline Perrigoue (Oreland, PA); Marion Vetter (Spring House, PA)

Assignee: Janssen Biotech, Inc.

C07K16/244A61P1/04A61P37/02C07K16/241A61K2039/505C07K2317/565

Abstract

Claims (25)

1. A method comprising:

a) administering to a group of patients with ulcerative colitis a first co-therapeutically effective amount of an anti-IL-23p19 antibody comprising (i) the heavy chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOS: 1-3 and the light chain CDR amino acid sequences of SEQ ID NOS: 4-6, (ii) the heavy chain variable region amino acid sequence of SEQ ID NO: 7 and the light chain variable region amino acid sequence of SEQ ID NO: 8, or (iii) the heavy chain amino acid sequence of SEQ ID NO: 9 and the light chain amino acid sequence of SEQ ID NO: 10;

b) administering to the group of patients with ulcerative colitis a second co-therapeutically effective amount of anti-TNF-α antibody comprising (i) the heavy chain CDR amino acid sequences of SEQ ID NOS: 11-13 and the light chain CDR amino acid sequences of SEQ ID NOS: 14-16, (ii) the heavy chain variable region amino acid sequence of SEQ ID NO: 17 and the light chain variable region amino acid sequence of SEQ ID NO: 18, or (iii) the heavy chain amino acid sequence of SEQ ID NO: 19 and the light chain amino acid sequence of SEQ ID NO: 20,

wherein the anti-TNF-α antibody and the anti-IL-23p19 antibody are administered in a ratio of from 1:2 to 2:1 (w/w); and

c) achieving one or more of the following clinical endpoints at week 12:

i. greater than 83 % of patients are in clinical response defined as a decrease from baseline in the Mayo score %≥30% and ≥3 points with either decrease form baseline in the rectal bleeding subscore (RBS) of ≥1 or a RBS of 0 or 1;

ii. greater that 36% of patients are in clinical remission defined as the Mayo score≤2 with no individual subscore>1;

iii. greater than 49% of patients have endoscopic healing defined as an endoscopy score of 0 or 1;

iv. greater than 80 % of patients have a modified Mayo response defined as a decrease form baseline in the modified Mayo score of ≥2 and ≥30%, plus a decrease in rectal bleeding subscore of ≥1 or an absolute rectal bleeding subscore of ≤1, wherein the modified Mayo score is calculated as the sub of the stool frequency, rectal bleeding, and endoscopy subscores; and

v. greater than 46% of patients are in clinical remission by health authority definition defined as a stool frequency subscore of 0 or 1, rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from baseline.

2. The method of claim 1 , wherein the anti-IL-23p19 antibody and the anti-TNF-α antibody are administered simultaneously.

3. The method of claim 1 , wherein the anti-IL-23p19 antibody and the anti-TNF-α antibody are administered sequentially.

4. The method of claim 1 , wherein the anti-IL-23p19 antibody and the anti-TNF-α antibody are administered within one day of one another.

5. The method of claim 1 , wherein the anti-IL-23p19 antibody is administered in an initial intravenous dose of 200 mg, intravenous doses of 200 mg at weeks 4 and 8 and subsequent subcutaneous doses of 100 mg every 8 weeks and the anti-TNF-α antibody is administered in an initial subcutaneous dose of 200 mg and subsequent subcutaneous doses of 100 mg at weeks 2, 6 and 10.

6. The method of claim 1 , wherein the anti-IL-23p19 antibody is in a pharmaceutical composition comprising a solution comprising 7.9% (w/v) sucrose, 4.0 mM Histidine, 6.9 mM L-Histidine monohydrochloride monohydrate, and 0.053% (w/v) Polysorbate 80 of the composition, and wherein the anti-TNF-α antibody is in a pharmaceutical composition comprising a solution comprising 4.1% (w/v) sorbitol, 5.6 mM L-Histidine and L-Histidine monohydrochloride monohydrate, and 0.015% (w/v) Polysorbate 80 of the composition.

7. A method comprising:

a) administering to a patient with ulcerative colitis a first co-therapeutically effective amount of an anti-IL-23p19 antibody comprising (i) a heavy chain variable region amino acid sequence of SEQ ID NO: 7 and a light chain variable region amino acid sequence of SEQ ID NO: 8, or (ii) a heavy chain amino acid sequence of SEQ ID NO: 9 and a light chain amino acid sequence of SEQ ID NO: 10;

b) administering to the patient with ulcerative colitis a second co-therapeutically effective amount of an anti-TNF-α antibody comprising (i) a heavy chain variable region amino acid sequence of SEQ ID NO: 17 and a light chain variable region amino acid sequence of SEQ ID NO: 18, or (ii) a heavy chain amino acid sequence of SEQ ID NO: 19 and a light chain amino acid sequence of SEQ ID NO: 20,

wherein the anti-TNF-α antibody and the anti-IL-23p19 antibody are administered simultaneously and in a ratio of from 1:2 to 2:1 (w/w); and

c) achieving one or more of the following clinical endpoints at week 12;

i. clinical response defined as a decrease from baseline in the Mayo score≥30% and ≥3 points with either decrease from baseline in the rectal bleeding subscore (RBS) of ≥1 or a RBS of 0 or 1;

ii. clinical remission defined as the Mayo score≤2 with no individual subscore>1;

iii. endoscopic healing defined as an endoscopy score of 0 or 1;

iv. modified Mayo response defined as a decrease from baseline in the modified Mayo score of ≥2 and ≥30%, plus a decrease in rectal bleeding subscore of ≥1 or an absolute rectal bleeding subscore of ≤1, wherein the modified Mayo score is calculated as the sum of the stool frequency, rectal bleeding, and endoscopy subscores; and

v. clinical remission by health authority definition defined as a stool frequency subscore of 0 or 1, rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, wherein the stool frequency subscore has not increased from baseline.

Assignments (1)

Continuity (3)

References Cited (400)